Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - canine adenovirus type 2 strain manhattan - live; canine distemper virus strain onderstepoort; canine parvovirus strain 154 - live - parenteral liquid/solution/suspension - canine adenovirus type 2 strain manhattan - live vaccine-viral active 0.0 tcid50; canine distemper virus strain onderstepoort vaccine-viral active 0.0 tcid50; canine parvovirus strain 154 - live vaccine-viral active 0.0 tcid50 - immunotherapy - dog - with exclusions see label - canine adenovirus - type 1 | canine adenovirus - type 2 | canine distemper | canine parvovirus | hepatitis :- infectious | canine adenovirus type 1 | canine adenovirus type 2 | infectious canine hepatitis | parvovirus

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - canine adeno virus type 2; canine distemper virus; canine parainfluenza virus; canine parvo virus - parenteral liquid/solution/suspension - canine adeno virus type 2 vaccine-viral active 0.0 tci50/do; canine distemper virus vaccine-viral active 0.0 tci50/do; canine parainfluenza virus vaccine-viral active 0.0 tci50/do; canine parvo virus vaccine-viral active 0.0 tci50/do - immunotherapy - dog - with exclusions see label - canine adenovirus - type 1 | canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | hepatitis :- infectious | respiratory disease | canine adenovirus type 1 | canine adenovirus type 2 | infectious canine hepatitis | parvovirus

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - aluminium hydroxide; bordetella bronchiseptica (inactivated cell free extract; canine parainfluenza virus - inactivated - misc. vaccines or anti sera - aluminium hydroxide mineral-aluminium-base active 3.0 mg/do; bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.05 ug/do; canine parainfluenza virus - inactivated vaccine-viral active 0.0 undefined - immunotherapy - dog - with exclusions see label - bordetella bronchiseptica | canine parainfluenza | canine cough syndrome | infectious tracheobronchitis

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bob martin (australia) pty ltd - malathion; liquid hydrocarbon - topical solution/suspension - malathion organophosphorus-dithiophospha active 200.0 g/l; liquid hydrocarbon solvent other 640.0 g/l - parasiticides - bird cage, cabinet, loft or aviary | cat - over 6 months old | dog - with exclusions see label | cat - over 24 weeks old - bird louse | flea | fowl tick | louse - felicola spp. | louse - trichodectes spp. | paralysis tick | poultry red mite | sarcoptic mange | tick - rhipicephalus spp. | australian paralysis tick | ctenocephalides spp. | ground fleas | red mite | scrub tick

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) b-cell acute lymphoblastic leukaemia (b-all).

Združene države Amerike - angleščina - myHealthbox

ecolab -

Združene države Amerike - angleščina - myHealthbox

ecolab -

Združene države Amerike - angleščina - NLM (National Library of Medicine)

citron pharma llc - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate 25 mg - topiramate tablets are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures. safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see clinical studies (14.1)] . topiramate tablets are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with lennox-gastaut syndrome [see clinical studies (14.2)] . topiramate tablets are indicated for adults for the prophylaxis of migraine headache [see clinical studies (14.3)]. the usefulness of topiramate tablets in the acute treatment of migraine headache has not been studied. additional pediatric use information for patients ages 12 to 17 years is approved for janssen pharmaceuticals, inc.’s topamax (t

Združene države Amerike - angleščina - NLM (National Library of Medicine)

major pharmaceuticals - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine fumarate tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6 week trials in adults. the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see clinical studies (14.1)].    pediatric use information in patients (13 to 17 years of age) with schizophrenia is approved for astrazeneca pharmaceuticals lp’s quetiapine fumarate drug product labeling. however, due to astrazeneca pharmaceuticals lp’s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, [see clinical studies (14.2) ]. quetiapine fum

Združene države Amerike - angleščina - NLM (National Library of Medicine)

cardinal health - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine fumarate tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6 week trials in adults. the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see clinical studies (14.1)].    pediatric use information in patients (13 to 17 years of age) with schizophrenia is approved for astrazeneca pharmaceuticals lp’s quetiapine fumarate drug product labeling. however, due to astrazeneca pharmaceuticals lp’s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, [see clinical studies (14.2) ]. quetiapine fum